A detailed history of Russell Investments Group, Ltd. transactions in Exelixis, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 980,368 shares of EXEL stock, worth $34.4 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
980,368
Previous 1,396,026 29.77%
Holding current value
$34.4 Million
Previous $31.4 Million 18.9%
% of portfolio
0.04%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$21.96 - $27.6 $9.13 Million - $11.5 Million
-415,658 Reduced 29.77%
980,368 $25.4 Million
Q2 2024

Aug 08, 2024

SELL
$20.34 - $23.73 $2.82 Million - $3.29 Million
-138,464 Reduced 9.02%
1,396,026 $31.4 Million
Q1 2024

May 08, 2024

BUY
$20.17 - $23.93 $421,532 - $500,113
20,899 Added 1.38%
1,534,490 $36.4 Million
Q4 2023

Feb 05, 2024

BUY
$19.25 - $24.13 $720,681 - $903,378
37,438 Added 2.54%
1,513,591 $36.3 Million
Q3 2023

Nov 13, 2023

BUY
$19.04 - $22.74 $1.2 Million - $1.43 Million
63,044 Added 4.46%
1,476,153 $32.3 Million
Q2 2023

Aug 10, 2023

BUY
$18.17 - $20.48 $9.61 Million - $10.8 Million
528,845 Added 59.81%
1,413,109 $27 Million
Q1 2023

May 09, 2023

BUY
$16.3 - $19.41 $4.18 Million - $4.97 Million
256,156 Added 40.78%
884,264 $17.2 Million
Q4 2022

Feb 08, 2023

SELL
$14.96 - $17.39 $43,593 - $50,674
-2,914 Reduced 0.46%
628,108 $10.1 Million
Q3 2022

Nov 04, 2022

BUY
$15.68 - $22.27 $3.1 Million - $4.4 Million
197,574 Added 45.58%
631,022 $9.89 Million
Q2 2022

Jul 29, 2022

BUY
$17.44 - $23.16 $399,184 - $530,109
22,889 Added 5.58%
433,448 $9.02 Million
Q1 2022

May 05, 2022

SELL
$17.03 - $22.67 $1.84 Million - $2.45 Million
-108,099 Reduced 20.84%
410,559 $9.3 Million
Q4 2021

Jan 21, 2022

BUY
$15.84 - $21.88 $722,193 - $997,574
45,593 Added 9.64%
518,658 $9.49 Million
Q3 2021

Nov 08, 2021

BUY
$16.3 - $21.14 $4.85 Million - $6.29 Million
297,637 Added 169.66%
473,065 $9.99 Million
Q2 2021

Aug 04, 2021

SELL
$17.95 - $25.56 $4.11 Million - $5.85 Million
-228,862 Reduced 56.61%
175,428 $3.19 Million
Q1 2021

May 10, 2021

BUY
$20.53 - $25.22 $2.93 Million - $3.6 Million
142,666 Added 54.53%
404,290 $9.12 Million
Q4 2020

Feb 08, 2021

BUY
$18.39 - $24.8 $1.07 Million - $1.45 Million
58,429 Added 28.76%
261,624 $5.25 Million
Q3 2020

Nov 09, 2020

SELL
$20.67 - $26.94 $598,107 - $779,535
-28,936 Reduced 12.47%
203,195 $4.97 Million
Q2 2020

Aug 05, 2020

BUY
$16.46 - $27.42 $1.55 Million - $2.59 Million
94,349 Added 68.48%
232,131 $5.5 Million
Q1 2020

May 06, 2020

BUY
$14.46 - $21.8 $979,173 - $1.48 Million
67,716 Added 96.65%
137,782 $2.38 Million
Q4 2019

Jan 29, 2020

BUY
$15.15 - $18.89 $255,519 - $318,598
16,866 Added 31.7%
70,066 $1.23 Million
Q3 2019

Nov 01, 2019

BUY
$17.68 - $22.65 $42,591 - $54,563
2,409 Added 4.74%
53,200 $940,000
Q2 2019

Aug 09, 2019

SELL
$18.93 - $24.75 $498,067 - $651,197
-26,311 Reduced 34.12%
50,791 $1.09 Million
Q1 2019

May 13, 2019

SELL
$19.6 - $24.76 $435,668 - $550,365
-22,228 Reduced 22.38%
77,102 $1.83 Million
Q4 2018

Feb 11, 2019

SELL
$13.65 - $21.8 $1.85 Million - $2.96 Million
-135,847 Reduced 57.76%
99,330 $1.95 Million
Q3 2018

Oct 26, 2018

BUY
$15.87 - $22.4 $2.79 Million - $3.94 Million
175,732 Added 295.62%
235,177 $4.17 Million
Q2 2018

Aug 08, 2018

SELL
$18.56 - $22.45 $1.53 Million - $1.85 Million
-82,407 Reduced 58.09%
59,445 $1.28 Million
Q1 2018

May 11, 2018

BUY
$22.15 - $31.89 $36,326 - $52,299
1,640 Added 1.17%
141,852 $3.14 Million
Q4 2017

Feb 06, 2018

SELL
$24.23 - $30.93 $3.27 Million - $4.17 Million
-134,896 Reduced 49.03%
140,212 $4.34 Million
Q3 2017

Nov 07, 2017

BUY
$23.35 - $29.24 $6.42 Million - $8.04 Million
275,108
275,108 $6.67 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.